Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Novel Format Conjugates February 2023

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Oct 21, 2022 4:17pm

105 Views

Post# 35040006

RE:RE:RE:RE:RE:RE:RE:Novel Format Conjugates February 2023

I think at this price, Paul can average down on his initial very large purchase when he was hired. Time to put a little money where your mouth is, as they say!

qwerty22 wrote:
Something has to happen in the clinic to get things moving.

Not everything they do is to directly address our woes. What Marsolais is doing is networking with people in the same boat as him, that should make him a better professional. I got no problem with him atm but we can all become better.

Biobob wrote: The simple fact that Marsolais is presenting pre-clinical data in Febuary 2023 (4 months from now) is a bit concerning... Is it me but something as got to happen overthere to get things moving. Are they up to the task in the end... maybe they lack the competence and the resources to get this trial moving at a normal pace. I'm starting to wonder.